Abstract | BACKGROUND: OBJECTIVE: METHODS: This study was performed during the 2003 grass pollen season as an open, randomized, parallel-group, single-center study of 123 patients assigned to receive mometasone furoate (200 microg once daily), levocabastine hydrochloride (200 microg twice daily), or disodium cromoglycate (5.6 mg 4 times daily). Symptom scores and nasal inspiratory peak flow measurements were recorded in a patient diary. The global efficacy of the study medication was evaluated by patients after treatment. Eosinophil cationic protein concentrations were measured in nasal secretions before and after treatment. Cost-effectiveness was evaluated as medication cost per treatment success. RESULTS: CONCLUSION:
|
Authors | Bernd Lange, Karl-Friedrich Lukat, Klaus Rettig, Gabriele Holtappels, Claus Bachert |
Journal | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
(Ann Allergy Asthma Immunol)
Vol. 95
Issue 3
Pg. 272-82
(Sep 2005)
ISSN: 1081-1206 [Print] United States |
PMID | 16200819
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Allergic Agents
- Piperidines
- Pregnadienediols
- Mometasone Furoate
- Eosinophil Cationic Protein
- levocabastine
- Cromolyn Sodium
|
Topics |
- Administration, Intranasal
- Adolescent
- Adult
- Anti-Allergic Agents
(administration & dosage, adverse effects, economics)
- Cromolyn Sodium
(administration & dosage, adverse effects, economics)
- Eosinophil Cationic Protein
(blood)
- Female
- Humans
- Male
- Middle Aged
- Mometasone Furoate
- Piperidines
(administration & dosage, adverse effects, economics)
- Pregnadienediols
(administration & dosage, adverse effects, economics)
- Respiratory Function Tests
- Rhinitis, Allergic, Seasonal
(drug therapy)
- Treatment Outcome
|